Children's Hospital Los Angeles cardiologist Michael Silka, MD, helped to pioneer the development of indications for the use of pacemakers and implantable defibrillators in young patients. From 1998 ...
A magnet in the new iPhone 12 can potentially disrupt the function of some implantable medical equipment, according to recent findings from a Michigan hospital system. Last month, cardiologists from ...
Add Yahoo as a preferred source to see more of our stories on Google. Electrocardiograms, or ECGs, record the electrical activity of your heart. Randy Faris/The Image Bank via Getty Images Your ...
MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Protecta™ portfolio of implantable cardioverter-defibrillators (ICDs) ...
The researchers found that women with nonischemic cardiomyopathy and an implantable cardioverter defibrillator had a lower risk for ventricular tachyarrhythmias or death compared to men. HealthDay ...
On October 4, 2001, Joshua Oukrop, a Minnesota teenager with hypertrophic cardiomyopathy and a high risk of sudden death from ventricular fibrillation, received an implantable ...
Medtronic is warning European healthcare providers of a potential safety issue found within many of its implanted heart devices that may make them less effective. As described in a June notice made ...
Headphones for MP3 players placed within an inch of pacemakers and implantable cardioverter defibrillators (ICDs) may interfere with these devices, according to research presented at the American ...
Dr. Morton M. Mower, a pioneering cardiologist and former Sinai Hospital staff member who was co-inventor of the automatic implantable cardioverter defibrillator, died of cancer Monday at Porter ...
Medical Device Network on MSN
Medtronic’s OmniaSecure defib lead nets another FDA approval
OmniaSecure is now the first defibrillation lead approved for placement in the left bundle branch.
The global implantable defibrillator market is projected to grow at a steady CAGR of ~7% during the forecast period, driven by rising cardiovascular disease prevalence, rapid technological innovation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results